Rheumatologists and gastroenterologists will be the first specialists in the United States and Europe who will have the opportunity to prescribe biosimilar monoclonal antibodies, such as infliximab. However, these specialists have, so far, had little first-hand experience with biosimilars. Understanding their familiarity with and perceptions of biosimilars is critical in determining how to position biosimilars in the immunology and infectious disease markets as well as for building a defense strategy against the imminent threat of biosimilars competition. We conducted primary market research with rheumatologists and gastroenterologists in the United States and Europe to understand their perspectives on biosimilars and their expected adoption rates. Based on our extensive market research, this report also provides highly granular, brand and biosimilar market forecasts for the United States, Europe, and Japan.
This immune and infectious diseases report is part of the Biosimilars Advisory Service. The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. Quarterly webinars detailing major developments, analyst insight addressing key market changes, therapeutic-area-specific primary research and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on BioTrends to keep you up-to-date on the biosimilars landscape and poised to maximize opportunities for your business.
Sample Frame & Methodology:
- This report is based on a quantitative survey of 91 rheumatologists and 94 gastroenterologists in the United States, France, and Germany.
- Markets covered: United States, Europe, and Japan
- Primary research: Quantitative 45-minute online survey of 91 rheumatologists and 94 gastroenterologists from the United States, France, and Germany.
- Quantitative online 45 minute survey of 94 gastroenterologists and 91 rheumatologists from the United States, France, and Germany
To qualify, respondents must meet the following criteria:
- Have worked in clinical practice for a minimum of 3 years and a maximum of 30 yea
- Work for a community hospital, private practice, or academic hospital (defined as having a large teaching facility).
- Spend more than 50% of their professional time in clinical practice if associated with an academic hospital or 75% of their professional time if based at a community hospital or private practice.
- Be familiar with the major biologic agents used in the treatment of immune diseases or hepatitis C virus.
- Final report in .ppt and .pdf format
- Live webinars highlighting key findings of the report and survey results
- Detailed market forecasts at the brand and biosimilar level, split by U.S., EU5 and Japan in .xls format
- Proprietary question slide decks and frequency tables
- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each therapy area
Related 2013 Reports:
- Acceptance of Biosimilars Across Physician Specialties
- Biosimilars Advisory Service: Corporate Strategies
- Biosimilars Advisory Service: Global Pipelines, Pathways, and Key Stakeholder Perceptions
- Biosimilars Advisory Service: Overall Physicians
- Biosimilars Advisory Service: US and EU Payer Perspectives
- Biosimilars Advisory Service: Endocrinology and Nephrology
- Biosimilars Advisory Service: Oncology
Key Terms for This Report:
- Market access
- Indication extrapolation
- Automatic substitution